

Effects of Benzo(e)pyrene on Reactive Oxygen/Nitrogen Species and Inflammatory Cytokines Induction in Human RPE Cells and Attenuation by Mitochondrial-involved Mechanism

M. Fernanda Estrago-Franco^{1,2}, MD; M. Tarek Moustafa^{1,3}, MD; Mohammad Riazi-Esfahani^{1,4}, MD
 Ashish U. Sapkal¹, MD; Rhina Piche-Lopez¹, MD; A. Jayaprakash Patil^{1,5}, MD; Ashish Sharma^{1,6}, MD
 Payam Falatoonzadeh¹, MD; Marilyn Chwa¹, MS; Georgia Luczy-Bachman⁷, MS
 Baruch D. Kuppermann¹, MD, PhD; M. Cristina Kenney¹, MD, PhD

¹Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA

²Clinica Dres Estrago, Corrientes, Argentina

³Ophthalmology Department, Minia University, Egypt

⁴Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁵Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Trust, Lancaster, UK

⁶Lotus Eye Care Hospital, Coimbatore, Tamil Nadu, India

⁷Department of Pediatrics, University of California, Irvine, CA, USA

Abstract

Purpose: To identify inhibitors that could effectively lower reactive oxygen/nitrogen species (ROS/RNS), complement and inflammatory cytokine levels induced by Benzo(e)pyrene [B(e)p], an element of cigarette smoke, in human retinal pigment epithelial cells (ARPE-19) *in vitro*.

Methods: ARPE-19 cells were treated for 24 hours with 200 μ M, 100 μ M, and 50 μ M B(e)p or DMSO (dimethyl sulfoxide)-equivalent concentrations. Some cultures were pre-treated with ROS/RNS inhibitors (NG nitro-L-arginine, inhibits nitric oxide synthase; Apocynin, inhibits NADPH oxidase; Rotenone, inhibits mitochondrial complex I; Antimycin A, inhibits mitochondria complex III) and ROS/RNS levels were measured with a fluorescent H₂DCFDA assay. Multiplex bead arrays were used to measure levels of Interleukin-6 (IL-6), Interleukin-8 (IL-8), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Transforming Growth Factor alpha (TGF- α) and Vascular Endothelial Growth Factor (VEGF). IL-6 levels were also measured by an enzyme-linked immunosorbent assay. Real-time qPCR analyses were performed with primers for C3

(component 3), CFH (inhibits complement activation), CD59 (inhibitor of the complement membrane attack complex (MAC)) and CD55/DAF (accelerates decay of target complement target proteins).

Results: The ARPE-19 cultures treated with B(e)p showed significantly increased ROS/RNS levels ($P < 0.001$), which were then partially reversed by 6 μ M Antimycin A (19%, $P = 0.03$), but not affected by the other ROS/RNS inhibitors. The B(e)p treated

Correspondence to:

M. Cristina Kenney, MD, PhD. Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Medical Center, 843 Health Science Road, Hewitt Hall, Rm 2028, Irvine, California 92697, USA.
 E-mail: mkenney@uci.edu

Received: 24-07-2016

Accepted: 28-09-2016

Access this article online

Quick Response Code:



Website:
www.jovr.org

DOI:
 10.4103/2008-322X.194091

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Estrago-Franco MF, Moustafa MT, Riazi-Esfahani M, Sapkal AU, Piche-Lopez R, Patil AJ, *et al.* Effects of Benzo(e)pyrene on reactive oxygen/nitrogen species and inflammatory cytokines induction in human RPE cells and attenuation by mitochondrial-involved mechanism. *J Ophthalmic Vis Res* 2016;11:385-93.

cultures demonstrated increased levels of IL-6 (33%; $P = 0.016$) and GM-CSF (29%; $P = 0.0001$) compared to DMSO-equivalent controls, while the expression levels for components of the complement pathway (C3, CFH, CD59 and CD55/DAF) were not changed.

Conclusion: The cytotoxic effects of B(e)p include elevated ROS/RNS levels along with pro-inflammatory IL-6 and GM-CSF proteins. Blocking the Qi site of cytochrome c reductase (complex III) with Antimycin A led to partial reduction in B(e)p induced ROS production. Our findings suggest that inhibitors for multiple pathways would be necessary to protect the retinal cells from B(e)p induced toxicity.

Keywords: Benzo(e)pyrene; Cytokines; Retinal Pigment Epithelium

J Ophthalmic Vis Res 2016; 11 (4): 385–393.

INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness and low vision in individuals over 55 years of age in the industrialized world.^[1] AMD can be classified into two types: wet or neovascular and dry or atrophic. In wet AMD, choroidal neovascular membrane (CNV) develops, which causes hemorrhage, swelling, and macular scarring resulting in severe visual loss. Dry AMD can result in atrophy of photoreceptors and retinal pigment epithelium (RPE) that can also decrease central vision over time. The combined prevalence of neovascular AMD and geographic atrophy has been estimated to be 1.4% in the United States, thus affecting 1.75 million individuals presently with a 50% expected increase by the year 2020.^[2] Although the clinical features of AMD have been well documented for more than a century, the detailed pathogenesis of AMD is not fully understood.^[3] However, cigarette smoking is one of the most consistent risk factors for AMD in several worldwide population based studies. In 1993, the Beaver Dam Eye Study showed that cigarette smoking increases the risk of wet AMD.^[4] Epidemiologic studies have confirmed that smoking is a risk factor in both forms of AMD.^[5]

A family of toxic compounds, the polycyclic aromatic hydrocarbons (PAH), are found in cigarette smoke, and they form DNA changes causing cellular proliferation. One of the most investigated PAH is Benzo(a)Pyrene [B(a)p] which has been shown to cause damage to bovine RPE cells^[6] and various other cell lines.^[7-9] The concentration of B(a)p in cigarette smoke is 9 ng/cigarette.^[10] More recently, another PAH compound, B(e)p which has a concentration of 5–40 ng/cigarette, was shown to decrease cell viabilities and induce apoptosis via multiple caspase pathways in human retinal pigment epithelial^[11] cells, human microvascular endothelial cells and rat retinal neurosensory cells.^[12] Furthermore, the damaging effects of B(e)p can be partially reversed by pre-treatment with memantine, resveratrol and genistein.^[13] B(e)p with its structure of five fused aromatic rings (PAH) with a high molecular weight^[14] can be found in substances besides cigarette smoke including automobile exhaust, charcoal-broiled foods, and incomplete combustion of organic materials.^[15]

Oxidative stress plays an important role in AMD as evident by the AREDS trial.^[16] There is mounting biochemical evidence of the role of oxidative stress in drusen formation, which is considered a hallmark of AMD.^[17] The superoxide radicals ($O^{\cdot -}$) are generated through two sources inside the cell, mitochondrial respiration^[18] (through complexes and pathways) or via the cell membrane bound NAD(P) H oxidase [Figure 1].^[19] The superoxide radical is converted to hydrogen peroxide (H_2O_2) by superoxide dismutases^[20,21] (SOD) and the H_2O_2 can be converted to O_2 and H_2O through enzymes such as glutathione synthase and catalase.^[21] Increased reactive oxygen/nitrogen species (ROS/RNS) levels are known to cause apoptosis through release of mitochondrial cytochrome C into the cytosol by opening the mitochondrial permeability transition pore.^[22,23] In addition, elevated ROS/RNS levels can contribute greatly to inflammation and oxidative damage by damaging proteins, lipids and DNA. If mitochondrial DNA (mtDNA) is damaged, then oxidative phosphorylation is diminished and additional ROS/RNS is generated. However, it is not clear how smoking




Figure 1. Schematic representation of intracellular pathways for superoxide, hydrogen peroxide, hydroxyl radical, nitric oxide and peroxynitrite productions. The mechanisms of detoxification and the sites of action of ROS/RNS inhibitors (thick solid black lines) are also shown. L-NNA, NG nitro-L-arginine; NAD(P)H, nicotinamide adenine dinucleotide phosphate; SOD, Superoxide dismutase; H_2O_2 , Hydrogen peroxide.

components might induce inflammation and oxidative damage in human RPE cells.

In addition to age and smoking, genetic factors play a major role in susceptibility to AMD. Recently, a strong genetic association has been described between AMD and Complement Factor H (CFH), which is a major plasma protein (155KDa) composed of 1213 amino acids,^[24] that is known to inhibit the alternative complement pathway.^[25] The pathological relevance of the genetic studies is supported by the demonstration that drusen contain complement proteins, including CFH,^[25-28] complement components C3,^[29,30] C2, CFB^[31,32] C5, Cq1, the membrane attack complex (MAC), and C5b-9.^[33] Increased serum levels of C3a have been reported in AMD patients.^[34] In addition, T-cell derived cytokines cause upregulation of complement pathway components including C3, CD46, CD55, CD59 and others.^[35]

CFH inhibits the C3b function, limits wasteful consumption of complement components and prevents non-specific damage to host tissues.^[2] After CFH binds to C3b, the complex interacts with complement receptors and complement factor B to promote opsonization and phagocytosis. This regulation occurs in both the fluid phase and cellular surfaces.^[36] Recent studies show that RPE cells produce CFH^[37] and also pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Interleukin-8 (IL-8).^[38] However, the response of CFH or cytokine levels from RPE cells after exposure to B(e)p have not been investigated. Therefore, the present study was designed to examine the effects of B(e)p on ROS/RNS production, pro-inflammatory cytokines and complement components.

METHODS

Cell Culture

ARPE-19 cells were obtained from ATCC (Manassas, VA). Cell passage numbers from 16–28 were used for these experiments. Cells were grown according to previously established methods.^[11] Cells were plated in 24 well plates (Becton Dickinson Labware, Franklin Lakes, NJ) for ROS/RNS (10^6 cells per well) assays. For the protein assay, 10^6 cells were plated in 60×15 mm well plates. The enzyme linked immunosorbent assay (ELISA) was performed in 96 well plates with 10^4 cells per well. When ARPE-19 cells became confluent, they were incubated for 24 hours in serum-free medium to make them relatively non-proliferating. This simulates the natural human RPE cells, which remain in a non-proliferating phase and which are not exposed to the circulation because of the outer blood-retinal barrier. The cells were exposed to varying concentrations of B(e)p.

Exposure to B(e)p

B(e)p was obtained from Sigma-Aldrich, St. Louis, MO, as a commercial powder. Concentrations of 200 μ M, 100 μ M

and 50 μ M B(e)p were used for the experiments. The stock solution of 100mM B(e)p was prepared by dissolving the B(e)p in dimethyl sulfoxide (DMSO). The working concentration of B(e)p was prepared by diluting the stock solution in the culture media. Previously, we showed that B(e)p treatment for 24 hours on ARPE-19 cells was cytotoxic,^[11] and hence this time point was chosen for the inhibition studies. The equivalent amounts of DMSO served as control cultures.

Pretreatment with Inhibitors

All inhibitors were obtained from Sigma-Aldrich (St. Louis, MO). Cells were pre-treated for 4 hours with one of the following enzyme inhibitors: 2, 4, or 6 μ M of Antimycin A (inhibitor of mitochondrial complex III); 30 or 60 μ M of Apocynin (inhibitor of NADPH oxidase); 100, 200 or 400 μ M of NG nitro-L-arginine (L-NNA; inhibitor of nitric oxide synthase) or 2 or 4 μ M of Rotenone (inhibitor of mitochondrial complex I). After inhibitor pretreatment, cells were incubated another 24 hours with 200 μ M B(e)p or DMSO-equivalent exposure (control) plus the inhibitor. The control cells were untreated cultures, the B(e)p treated cultures and DMSO-equivalent treated cultures. Experiments were repeated at three separate times in duplicates.

Detection of ROS/RNS

ROS/RNS production was measured with the fluorescent dye 2',7'-dichlorodihydro fluorescein diacetate assay (H_2DCFDA ; Invitrogen) which detects H_2O_2 , hydroxyl radicals, and peroxy nitrite anions. Briefly, the ARPE-19 cells were plated in 24-well plates. The cells were washed with sterile phosphate buffered saline (PBS), and incubated with 500 μ l of 10 μ M H_2DCFDA for 15 minutes at 37°C and again washed with PBS. The H_2DCFDA (10 μ M) was prepared by adding 2 μ l of 5 mM (H_2DCFDA) stock/ml in PBS. The 5 mM H_2DCFDA stock solution was prepared fresh by mixing 0.001 g of H_2DCFDA in of DMSO. ROS/RNS production was measured with the fluorescence imager (excitation 488 nm, emission 520 nm, (FMBIO III; Hitachi, Yokohama, Japan).

Screening for Cytokines Levels

The expressions of cytokines from the supernatant of B(e)p treated and DMSO-equivalent treated ARPE-19 cultures were measured using the multiplex bead array format (Luminex, Austin, TX). The high sensitivity multiplex assay kit was used to obtain simultaneous quantitative determination of the human cytokines. The array was analyzed as per manufacturer's instructions. The increased levels of IL-6 levels in the supernatant of ARPE-19 cell cultures were verified with the quantitative sandwich enzyme linked immunoassay technique (ELISA;

R & D Systems, Minneapolis, MN). The ELISA assay was performed as per manufacturer's instructions. The substrate solution color intensity was measured using a Molecular Devices Spectra Max Plus 384 spectrophotometer.

Isolation of RNA and Amplification of cDNA

Cells from untreated and B(e)p treated cultures were pelleted, and RNA isolated using the RNeasy Mini-Extraction kit (Qiagen) following the manufacturer's protocol. The RNA was quantified using a NanoDrop 1000 (ThermoScientific). For Q-PCR analyses, 100 ng of individual RNA samples were reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen).

Real-time Quantitative PCR (RT-qPCR) Analyses

RT-qPCR was performed using 4 different primers (QuantiTect Primer Assay, Qiagen) for genes associated with the complement pathway (C3, CFH, CD59, CD55/DAF) [Table 1]. The Q-PCR using the QuantiFast SYBR Green PCR Kit (Qiagen) and a Bio-Rad iCycler iQ5 detection system was performed using the cDNA samples from the untreated and B(e)p treated cultures. TBP gene was used as a housekeeper. The analyses were performed in triplicate and the experiments were repeated twice. Statistical analyses of gene expression levels were performed to measure difference between haplogroups using Prism, Version 5.0 (GraphPad Software Inc.).

Statistical Analysis

Data from all experiments was analyzed by Student's t Test (GraphPad Prism, version 3.0; GraphPad Software

Inc., San Diego, CA) and presented as Mean \pm Standard Error of Mean (SEM). Statistically significant values were denoted as (*), (**) and (***) on the figures for *P* values <0.05, <0.01 and <0.001 respectively.

RESULTS

Inhibitors were tested to determine whether they could block the ROS/RNS levels that were induced by 200 μ M B(e)p [Figure 1]. DMSO-treated cultures were standardized to 100%. Antimycin A 6 μ M reduced the ROS/RNS levels to $260.7 \pm 23.01\%$ ($P = 0.03$), from the B(e)p induced ROS/RNS level of $311.1 \pm 22.55\%$. The 2 μ M and 4 μ M Antimycin A did not block the ROS/RNS levels. In addition, the other inhibitors, Apocynin, L-NNA and Rotenone, did not reverse B(e)p induced ROS/RNS levels [Figure 2a-d].

Supernatants of the ARPE-19 cell cultures treated with 50, 100 and 200 μ M B(e)p or DMSO-equivalent controls were analyzed with the multiplex bead array, which scanned for IL-6, IL-8, GM-CSF, TGF- α and VEGF proteins. These analyses showed significantly higher levels of IL-6 and GM-CSF in the B(e)p treated cultures as compared to the DMSO-equivalent treated cultures [Figure 3]. After B(e)p treatment, there was a 33% increase of IL-6 levels (133.0 ± 8.1 versus 99.9 ± 0.06 , $P = 0.016$) and 28.7% higher GM-CSF levels (128.7 ± 0.33 versus 99.9 ± 0.06 , $P = 0.0001$). There were no significant changes between the B(e)p treated and DMSO-equivalent control cultures for the levels for IL-8 (101.7 ± 3.9), TGF- α (110.0 ± 8.08) and VEGF (85.3 ± 6.68). As IL-6 is a well-recognized pro-inflammatory cytokine, we wanted to further analyze this response at different B(e)p concentrations. Therefore, ARPE-19 cells were exposed

Table 1. Q-PCR analyses for gene expression of complement genes after treatment with B(e)p versus DMSO-equivalent

Symbol	Gene Name	GenBank accession no	Function	<i>p</i>	$\Delta\Delta$ CT/Fold ^a
C3	Complement Component 3	NM_000064	Central in activation of complement system; required for both classical and alternative pathways	0.59	0.195 \pm 0.350/1.14
CFH	Complement Factor H	NM_000186	Essential in regulation of complement activation	0.44	0.133 \pm 0.166/1.10
CD59	CD59 Molecule, Complement Regulatory Protein	NM_000611 NM_203329 NM_203331 NM_001127223 NM_001127225 NM_001127226 NM_001127227	Cell surface glycoprotein that regulates complement-mediated cell lysis, inhibits complement membrane attack complex and is involved in lymphocyte signal transduction	0.75	-0.0483 \pm 0.146/0.97
CD55/DAF	Decay accelerating factor for complement	NM_000574 NM_001114543 NM_001114544 NM_00111475	Involved in the regulation of complement cascade by accelerating the decay of complement proteins and disrupting the cascade	0.52	-0.172 \pm 0.260/0.89

^aN=3 with six values for each sample. Positive values indicate up regulation of the gene. Negative values indicate down regulation of the gene. Fold=2^{- $\Delta\Delta$ CT}. DMSO, dimethyl Sulfoxide; L-NNA, NG nitro-L-arginine; ROS/RNS, reactive oxygen/nitrogen species




Figure 2. (a) ROS/RNS levels in ARPE-19 cells; L-NNA at 100, 200 and 400 μM concentrations did not change ROS/RNS production levels compared to the 200 μM B(e)p treated cultures. The ROS/RNS levels for 200 μM B(e)p were increased to $347.4\% \pm 52.36\%$ ($***P = 0.001$), significant compared to standardized DMSO controls (100%). (b) ROS/RNS levels in ARPE-19 cells; Apocynin at 30 and 60 μM concentrations did not reverse the ROS/RNS production levels compared to the 200 μM B(e)p treated cultures. ROS/RNS levels in the 200 μM B(e)p cultures were higher $219.0 \pm 11.90\%$ as compared to standardized DMSO controls (100%, $***P < 0.001$). (c) ROS/RNS levels in ARPE-19 cells; Rotenone at 2 and 4 μM concentrations did not reverse ROS/RNS production levels compared to the B(e)p treated cultures. The ROS/RNS levels for 200 μM B(e)p were increased ($156.8 \pm 20.93\%$) compared to standardized DMSO controls (100%, $*P < 0.05$). (d) ROS/RNS levels in ARPE-19 cells. The cultures pretreated with Antimycin A 6 μM concentration showed reduced ROS/RNS levels ($241.2 \pm 19.85\%$) compared to the 200 μM B(e)p treated cultures ($311.1 \pm 22.55\%$, $*P < 0.05$). The ROS/RNS levels in the 200 μM B(e)p treated cultures were significantly higher compared to standardized DMSO-equivalent treated controls (100%, $***P < 0.001$). This finding indicates that the mitochondrial complex III was involved in ROS/RNS generation after B(e)p treatment. DMSO, dimethyl sulfoxide; L-NNA, NG Nitro-L-arginine; ROS/RNS, oxygen/nitrogen species.

to 50 μM , 100 μM or 200 μM B(e)p and IL-6 levels were measured using an ELISA assay. B(e)p 200 μM versus DMSO-equivalent comparisons were 62.99 ± 0.05 versus 49.07 ± 0.10 ($P < 0.001$, $n = 3$); B(e)p 100 μM versus DMSO-equivalent comparisons were 70.30 ± 0.33 versus 51.16 ± 0.19 ($P < 0.001$); and B(e)p 50 μM versus DMSO-equivalent comparisons were 83.02 ± 0.06 versus 60.27 ± 0.29 ($P < 0.001$) [Figure 4].

The RT-qPCR results of cells treated with B(e)p showed that there was no increased expression of the C3 (1.14 fold, $P = 0.59$), CFH (1.10 fold, $P = 0.44$), CD59 (0.97 fold, $P = 0.75$) or CD55/DAF (0.89 fold, $P = 0.52$) genes, all of which are involved with the complement pathway, compared to the untreated cultures [Table 1].

DISCUSSION

Retinal and choroidal tissues have some of the highest oxygen consumption rates in the body.^[39] This large oxygen gradient, along with high levels of polyunsaturated fatty acids in photoreceptors and




Figure 3. Luminex Multiplex bead array. After B(e)p treatment, ARPE-19 cell supernatant showed 33% increase in IL-6 levels (133 ± 8.1 vs. 99.90 ± 0.06 , $*P < 0.05$) and approximately 28% higher GM-CSF levels (128.7 ± 0.33 vs. 99.90 ± 0.06 , $***P < 0.001$). DMSO, dimethyl sulfoxide; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; TGF- α , transforming growth factor alpha; VEGF, vascular endothelial growth factor.

repeated exposure to light, make a highly oxidative milieu.^[40] The retinal micro-environment is highly sensitive to these events, which ultimately elevates the levels of oxidative stress, a major pathological factor in AMD.

Smoking is one of the environmental factors proven in several studies to contribute to AMD.^[4,5] A number of toxic compounds exist in cigarette smoke and one of the well-known agents is B(e)p belonging to a group of polycyclic aromatic hydrocarbons. In our previous study, ARPE-19 cells showed a concentration-dependent decrease in cell viability after exposure to B(e)p.^[11] In addition, B(e)p promoted apoptosis through activation of multiple caspases, which could be inhibited by exposure to memantine, resveratrol and genistein.^[13]

ROS and RNS are powerful oxidizing agents produced in different compartments of the cell. Figure 1 provides a simplified schematic presentation of different pathways for ROS/RNS production and their fate. Within the retinal cells, the mitochondria are the major sites of ROS production^[41] with superoxides being generated at complex III (inhibited by Antimycin A)^[42,43] and complex I (inhibited by Rotenone)^[44] of the electron transport chain (ETC). A non-mitochondrial source of superoxide formation is the membrane bound NADPH oxidase (inhibited by Apocynin).^[45-47] Superoxide is an unstable molecule that is rapidly converted to H_2O_2 by superoxide dismutase (SOD). If the H_2O_2 molecule is processed through the Fenton reaction, the destructive hydroxyl radical will be formed. Alternatively, the superoxide can react with nitric oxide, which is produced by nitric oxide synthase (inhibited by L-NNA) to form peroxynitrite, another powerful oxidizing agent. By knowing the exact site of action for each of the inhibitors and measuring ROS/RNS in the B(e)p treated RPE cell




Figure 4. High IL-6 levels detected with Quantikine (ELISA) assay in supernatant of the 50, 100 and 200 μM B(e)p treated ARPE-19 cell cultures compared to the DMSO-equivalent treated control cultures (100%, *** $P < 0.001$). DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; IL, interleukin.

cultures, we can speculate the most probable site of action of B(e)p for its destructive effects. In our study, 6 μM Antimycin A partially reversed ROS/RNS production in B(e)p exposed cells, suggesting that mitochondrial complex III is a site of action for B(e)p. Antimycin A is known to the H_2O_2 hydrogen peroxide production (a contributor towards ROS/RNS levels) in isolated rat cardiac subsarcolemmal mitochondria in normal conditions.^[42] One of the explanations is electron leakage and superoxide production to the cytoplasmic face of the mitochondrial membrane and its conversion to hydrogen peroxide (because center of complex III resides in cytoplasmic side of mitochondrial membrane).^[48] Antimycin A has also been shown to cause cell death by increasing hydrogen peroxide production in HeLa cells.^[49] Antimycin A at 1 μM dose has also been shown to increase complement regulatory protein DAF (decay accelerating factor) in cultured ARPE-19 cells.^[50]

Our findings show that B(e)p increases oxidative stress and pro-inflammatory cytokine levels, thus suggesting the damage caused by B(e)p in ARPE-19 cells is similar to known pathogenic mechanisms for AMD. Previously, Kim JH et al^[51] used 0.2 μM Rotenone on H_2O_2 stressed ARPE-19 to increase the ROS/RNS production. In our study, Rotenone and Apocynin did not diminish the ROS/RNS production in B(e)p treated cells, suggesting that it does not act through mitochondrial complex I or NADPH oxidase. The ROS/RNS assay used in this study also measures the combined levels of H_2O_2 , hydroxyl and peroxynitrite. The latter is generated by combination of superoxide and nitric oxide, which can reportedly cause vascular endothelial toxicity.^[52-54] Nitric oxide, which is formed by nitric oxide synthase activity, can induce retinal angiogenesis.^[55,56] The nitric oxide synthase inhibitor, L-NNA, prevents the formation of nitric oxide and subsequently peroxynitrite formation.^[57] In the present study, L-NNA was evaluated at three different dosages (400, 200 and 100 μM) and found to have no effect in blocking the B(e)p induced ROS/RNS

production, which indicates that B(e)p does not act via the nitric oxide pathway. One possible limitation of our study is that the assay measures multiple types of ROS/RNS. However, the inhibitors used are very specific and if the pathways were involved, we would expect a decline in the ROS/RNS values after inhibitor treatment. On the other hand, different components of ROS/RNS can readily convert to each other and we are going to deal the oxidative stress of B(e)p (as a whole) on RPE cells. Then, our method of ROS/RNS measurement would be useful to find a way to attenuate total destructive effects of B(e)p as a whole. By the way, our study showed that only one of the inhibitors (Antimycin A), which only acts on mitochondrial complex III, attenuates the oxidizing action of B(e)p and provides guidance to focus on the mitochondrial respiratory chain.

Our RT-qPCR data provides *in vitro* evidence that B(e)p did not change the expression levels for any of the complement pathway components. In general, CFH plays a critical protective role in host cells against inflammation and diseases. Both increased age and smoking decrease plasma levels of CFH^[58,59] and CFH deficiency is associated with uncontrolled complement activation along with cellular and tissue damage. Dysregulation of the complement pathway plays an important role in the development of AMD.^[42] It has been shown that RPE cells are a local source of CFH^[60] and *in vitro* studies have shown that mouse and human RPE cells produce significant amounts of CFH protein. Although it has been shown that RPE synthesis of CFH is suppressed by pro-inflammatory proteins and oxidized photoreceptor rod outer segment,^[42] in our study the ARPE-19 cultures showed increased IL-6 levels after B(e)p treatment but no change in CFH expression. This is in contrast with another study which showed extensive increase in gene expression of C3, CFH and CD59 in RPE cells 24 hours after exposure to B(a)p (another member of the PAH molecules).^[61] Marazita et al recently applied cigarette smoke concentrate and hydrogen peroxide to ARPE-19 to make them senescent. Those senescent ARPE-19 cells showed upregulated IL-6, IL-8, VEGF and simultaneously downregulated CFH expression.^[62] In our study we could not find any significant changes in VEGF. The difference between study results may be due to the presence of other components of the cigarette smoke or hypoxia, which could have additive effects to the B(e)p exposure. Our study has been done at the gene level on complement factors, but more studies at the protein level could clarify the amount of each complement factor in this situation and could better explain those changes after B(e)p treatment.

IL-6 is a potent pro-inflammatory cytokine that binds to its receptor and the complex then interacts with gp130 on the cell surface. This leads to dimerization of gp130 which in turn initiates IL-6-mediated signaling in target cells^[63] through the activation of signal transducer and activator

of transcription 3 (STAT3), a known transcription factor that induces inflammation^[64] and extracellular signal-regulated kinase and mitogen-activated protein kinase (ERK-MAP kinase) cascade, which mainly promotes cell proliferation.^[65] Increased serum levels of IL-6 are related to AMD progression.^[66] Formation of CNV by laser treatment caused IL-6 expression in the RPE-choroid complex. Significant suppression of CNV happened due to antibody-based blockade of IL-6 receptor or genetic ablation of IL-6.^[67] The present study demonstrated that after 24 hours of treatment with B(e)p, the ARPE-19 cells showed significant increase of IL-6 levels. These findings suggest that the cigarette smoke element B(e)p could elevate IL-6 levels and possibly contribute to the inflammatory environment found in retinal diseases such as AMD. Further animal studies will be necessary to verify our tissue culture findings.

In ARPE-19 cultures, B(e)p induced a 28% increase in GM-CSF levels ($P = 0.0001$). GM-CSF is a glycoprotein that has been localized to the retina^[68] and functions to stimulate differentiation of hematopoietic progenitor cells into tissue-resident dendritic cells, macrophages and granulocytes.^[69] Recent studies suggest neuro-protective properties of GM-CSF in cerebral neurons and retinal cells.^[69,70] While GM-CSF has been associated with retinal ganglion cells,^[68] this is the first study to show that it is produced by the ARPE-19 cells. The significance of higher levels of GM-CSF after B(e)p treatment is speculative and requires further investigation.

In summary, we found that smoking component B(e)p generates ROS/RNS most probably through mitochondrial complex III and induces inflammatory processes through IL-6 and GM-CSF, which makes them targets for drug therapy to diminish the levels of oxidative stress and inflammation in human RPE cells.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.

REFERENCES

- Hawkins BS, Bird A, Klein R, West SK. Epidemiology of age-related macular degeneration. *Mol Vis* 1999;5:26.
- Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol* 2004;122:564-572.
- Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. *Trends Mol Med* 2004;10:417-420.
- Klein R, Klein BE, Linton KL, DeMets DL. The Beaver Dam Eye Study: The relation of age-related maculopathy to smoking. *Am J Epidemiol* 1993;137:190-200.
- Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. *Am J Hum Genet* 2006;78:852-864.
- Patton WP, Routledge MN, Jones GD, Lewis SE, Archer DB, Davies RJ, et al. Retinal pigment epithelial cell DNA is damaged by exposure to benzo[a]pyrene, a constituent of cigarette smoke. *Exp Eye Res* 2002;74:513-522.
- Hockley SL, Arlt VM, Brewer D, Giddings I, Phillips DH. Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2. *BMC Genomics* 2006;7:260.
- Sanyal MK, Li YL. Differential metabolism of benzo[alpha]pyrene *in vitro* by human placental tissues exposed to active maternal cigarette smoke. *Birth Defects Res B Dev Reprod Toxicol* 2007;80:49-56.
- Sugihara N, Toyama K, Okamoto T, Kadowaki M, Terao K, Furuno K. Effects of benzo(e)Pyrene and benzo(a)pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer: A comparative approach. *Toxicol In Vitro* 2007;21:827-834.
- Sellakumar A, Shubik P. Carcinogenicity of different polycyclic hydrocarbons in the respiratory tract of hamsters. *J Natl Cancer Inst* 1974;53:1713-1719.
- Sharma A, Neekhra A, Gramajo AL, Patil J, Chwa M, Kuppermann BD, et al. Effects of BenzoS(e)Pyrene, a toxic component of cigarette smoke, on human retinal pigment epithelial cells *in vitro*. *Invest Ophthalmol Vis Sci* 2008;49:5111-5117.
- Patil AJ, Gramajo AL, Sharma A, Seigel GM, Kuppermann BD, Kenney MC. Differential effects of nicotine on retinal and vascular cells *in vitro*. *Toxicology* 2009;259:69-76.
- Mansoor S, Gupta N, Patil AJ, Estrago-Franco MF, Ramirez C, Migon R, et al. Inhibition of apoptosis in human retinal pigment epithelial cells treated with BenzoS(e)Pyrene, a toxic component of cigarette smoke. *Invest Ophthalmol Vis Sci* 2010;51:2601-2607.
- Biggs WR, Fetzer JC. Electronic spectral detection in liquid chromatography. *Anal Bioanal Chem* 2002;373:368-77.
- Zedek MS. Polycyclic aromatic hydrocarbons: A review. *J Environ Pathol Toxicol* 1980;3:537-567.
- AREDS report no. 9. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. *Arch Ophthalmol* 2001;119:1439-1452.
- Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. *Nat Med* 2008;14:194-198.
- Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J* 1973;134:707-716.
- Schulz E, Anter E, Keaney JF Jr. Oxidative stress, antioxidants, and endothelial function. *Curr Med Chem* 2004;11:1093-1104.
- McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocyte cuprein (hemocuprein). *J Biol Chem* 1969;244:6049-6055.
- Wilcox CS. Reactive oxygen species: Roles in blood pressure and kidney function. *Curr Hypertens Rep* 2002;4:160-166.
- Pastorino JG, Tafani M, Rothman RJ, Marcinkewiciute A, Hoek JB, Farber JL. Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore. *J Biol Chem* 1999;274:31734-31739.
- Petronilli V, Penzo D, Scorrano L, Bernardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings *in situ*. *J Biol Chem* 2001;276:12030-12034.
- Susukida R, Kido A, Oya M, Mabuchi T. Genetic analysis of human complement factor H polymorphisms. *Electrophoresis* 2007;28:309-316.

25. Coffey PJ, Gias C, McDermott CJ, Lundh P, Pickering MC, Sethi C, et al. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. *Proc Natl Acad Sci U S A* 2007;104:16651-16656.
26. Edwards, A.O., Ritter, R., 3rd, Abel, K.J., Manning, A., Panhuysen, C., Farrer, L.A. Complement factor H polymorphism and age-related macular degeneration. *Science* 2005;308:421-424.
27. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. *Science* 2005;308:419-421.
28. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. *Science* 2005;308:385-389.
29. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. *Nat Genet* 2007;39:1200-1201.
30. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. Complement C3 variant and the risk of age-related macular degeneration. *N Engl J Med* 2007;357:553-561.
31. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat Genet* 2006;38:458-462.
32. Spencer KL, Hauser MA, Olson LM, Schmidt S, Scott WK, Gallins P, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. *Hum Mol Genet* 2007;16:1986-1992.
33. Chen M, Forrester JV, Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. *Exp Eye Res* 2007;84:635-645.
34. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR, et al. Estimation of systemic complement C3 activity in age-related macular degeneration. *Arch Ophthalmol* 2007;125:515-519.
35. Juel HB, Kaestel C, Folkersen L, Faber C, Heegaard NH, Borup R, et al. Retinal pigment epithelial cells upregulate expression of complement factors after co-culture with activated T cells. *Exp Eye Res* 2011;92:180-188.
36. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: Genetics and disease associations of human complement factor H. *Clin Exp Immunol* 2008;151:1-13.
37. Kim YH, He S, Kase S, Kitamura M, Ryan SJ, Hinton DR. Regulated secretion of complement factor H by RPE and its role in RPE migration. *Graefes Arch Clin Exp Ophthalmol* 2009;247:651-659.
38. Leung KW, Barnstable CJ, Tombran-Tink J. Bacterial endotoxin activates retinal pigment epithelial cells and induces their degeneration through IL-6 and IL-8 autocrine signaling. *Mol Immunol* 2009;46:1374-1386.
39. Yu DY, Cringle SJ. Retinal degeneration and local oxygen metabolism. *Exp Eye Res* 2005;80:745-751.
40. Jarrett SG, Boulton ME. Consequences of Oxidative Stress in Age Related Macular Degeneration. *Mol Aspects Med* 2012;33:399-417.
41. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. *Ann N Y Acad Sci* 2000;899:136-147.
42. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: Central role of complex III. *J Biol Chem* 2003;278:36027-36031.
43. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. *Cell* 2005;120:483-495.
44. Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, et al. Simvastatin effects on skeletal muscle: Relation to decreased mitochondrial function and glucose intolerance. *J Am Coll Cardiol* 2013;8:61:44-53.
45. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res* 1994;74:1141-1148.
46. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. *Am J Respir Cell Mol Biol*. 1994;11:95-102.
47. Barbieri SS, Cavalca V, Eligini S, Brambilla M, Caiani A, Tremoli E, et al. Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms. *Free Radic Biol Med* 2004;37:156-165.
48. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of Superoxide Production from Different Sites in the Mitochondrial Electron Transport Chain. *J Biol Chem* 2002;277:44784-44790.
49. Park WH1, Han YW, Kim SH, Kim SZ. An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. *J Cell Biochem*. 2007;102:98-109.
50. Anderson RE, LaVail MM, Hollyfield JG, Mandal MNA. Retinal degenerative diseases: Laboratory and therapeutic investigations. London: Springer, New York; 2010.
51. Kim JH, Kim JH, Jun HO, Yu YS, Min BH, Park KH. Protective effect of clusterin from oxidative stress-induced apoptosis in human retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* 2010;51:561-566.
52. Beckman JS1, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci U S A* 1990;87:1620-1624.
53. Halliwell B, Zhao K, Whiteman M. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good: A personal view of recent controversies. *Free Radic Res* 1999;31:651-669.
54. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. *Annu Rev Pharmacol Toxicol* 2001;41:203-236.
55. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. *J Clin Invest* 2001;107:717-725.
56. Ando A, Yang A, Mori K, Yamada H, Yamada E, Takahashi K, et al. Nitric oxide is proangiogenic in the retina and choroid. *J Cell Physiol* 2002;191:116-124.
57. Faraci FM, Heistad DD. Does basal production of nitric oxide contribute to regulation of brain-fluid balance? *Am J Physiol* 1992;262:H340-344.
58. Esparza-Gordillo J1, Soria JM, Buil A, Almasy L, Blangero J, Fontcuberta J, et al. Genetic and environmental factors influencing the human factor H plasma levels. *Immunogenetics* 2004;56:77-82.
59. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. *JAMA* 2004;291:704-710.
60. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc Natl Acad Sci U S A* 2005;102:7227-7232.
61. Wang AL, Lukas TJ, Yuan M, Du N, Handa JT, Neufeld AH. Changes in retinal pigment epithelium related to cigarette smoke: Possible relevance to smoking as a risk factor for age-related macular degeneration. *PLoS One* 2009;4:e5304.
62. Marazita MC, Dugour A, Marquioni-Ramella MD, Figueroa JM, Suburo AM. Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: Implications for Age-related Macular Degeneration. *Redox Biol* 2016;7:78-87.
63. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. *Cell* 1990;63:1149-1157.
64. Alonzi T, Fattori E, Cappelletti M, Ciliberto G, Poli V. Impaired

- Stat3 activation following localized inflammatory stimulus in IL-6-deficient mice. *Cytokine* 1998;10:13-18.
65. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. *J Immunol* 1997;159:2212-2221.
66. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: Prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. *Arch Ophthalmol* 2005;123:774-782.
67. Izumi-Nagai K, Nagai N, Ozawa Y, Mihara M, Ohsugi Y, Kurihara T, et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. *Am J Pathol* 2007;170:2149-2158.
68. Schallenberg M, Charalambous P, Thanos S. GM-CSF regulates the ERK1/2 pathways and protects injured retinal ganglion cells from induced death. *Exp Eye Res* 2009;89:665-677.
69. Schäbitz WR, Krüger C, Pitzer C, Weber D, Laage R, Gassler N, et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). *J Cereb Blood Flow Metab* 2008;28:29-43.
70. Kruger C, Laage R, Pitzer C, Schabitz WR, Schneider A. The hematopoietic factor GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of adult neural stem cells *in vitro*. *BMC Neurosci* 2007;8:88.